Free Trial
NASDAQ:DCTH

Delcath Systems Q2 2023 Earnings Report

Delcath Systems logo
$11.12 +0.24 (+2.19%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Delcath Systems EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Delcath Systems Revenue Results

Actual Revenue
$0.50 million
Expected Revenue
$0.73 million
Beat/Miss
Missed by -$230.00 thousand
YoY Revenue Growth
N/A

Delcath Systems Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
8:00AM ET

Delcath Systems Earnings Headlines

Trump’s AI Agenda: The 9 stocks poised to benefit most
While many are busy chasing the usual AI trends, a bigger opportunity is quietly brewing—and most are missing it. Imagine a major shift in how and where AI is built, opening up incredible wealth opportunities for those in the know. I’ve found 9 AI companies primed to lead this change. These aren’t the tired “AI hype” stocks; they’re companies with real US operations, proven revenue growth, and deep AI integration.
Wall Street Zen Downgrades Delcath Systems (NASDAQ:DCTH) to Hold
HC Wainwright Forecasts Weaker Earnings for Delcath Systems
See More Delcath Systems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Delcath Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Delcath Systems and other key companies, straight to your email.

About Delcath Systems

Delcath Systems (NASDAQ:DCTH), an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

View Delcath Systems Profile

More Earnings Resources from MarketBeat